Abstract:It has been well established that cancer cells can evade immune surveillance by mutating themselves. Understanding genetic alterations in cancer cells that contribute to immune regulation could lead to better immunotherapy patient stratification and identification of novel immune-oncology (IO) targets. In this report, we describe our effort of genome-wide association analyses across 22 TCGA cancer types to explore the associations between genetic alterations in cancer cells and 76 immune traits. Results showed that the tumor microenvironment (TME) is shaped by different gene mutations in different cancer types. Out of the key genes that drive multiple immune traits, top hit KEAP1 in lung adenocarcinoma (LUAD) was selected for validation. It was found that KEAP1 mutations can explain more than 10% of the variance for multiple immune traits in LUAD. Using public scRNA-seq data, further analysis confirmed that KEAP1 mutations activate the NRF2 pathway and promote a suppressive TME. The activation of the NRF2 pathway is negatively correlated with lower T cell infiltration and higher T cell exhaustion. Meanwhile, several immune check point genes, such as CD274 (PD-L1), are highly expressed in NRF2-activated cancer cells. By integrating multiple RNA-seq data, a NRF2 gene signature was curated, which predicts anti-PD1 therapy response better than CD274 gene alone in a mixed cohort of different subtypes of non-small cell lung cancer (NSCLC) including LUAD, highlighting the important role of KEAP1-NRF2 axis in shaping the TME in NSCLC. Finally, a list of overexpressed ligands in NRF2 pathway activated cancer cells were identified and could potentially be targeted for TME remodeling in LUAD. Recent studies have found that some genetic changes help cancer cells to evade the immune surveillance. To systematically understand the impact of cancer cell genetic alterations to immune regulation, we examined 76 immune traits across 22 cancer types. The tumor microenvironment (TME), crucial for cancer development, varies based on gene mutations in different cancers. Notably, the KEAP1 gene in lung adenocarcinoma (LUAD) emerged as a key player, explaining over 10% of immune trait variations. KEAP1 mutations activate the NRF2 pathway, creating a suppressive TME in LUAD with lower T cell infiltration and heightened T cell exhaustion. Additionally, genes such as CD274 (PD-L1), associated with immune checkpoints, exhibit high expression in NRF2-activated cancer cells. By developing a NRF2 gene signature, we found that it more effectively predicts anti-PD1 therapy responses than CD274 alone in non-small cell lung cancer. Lastly, we identified ligands overexpressed in NRF2-activated cancer cells, suggesting potential targets for reshaping the LUAD microenvironment. In essence, understanding these genetic interactions helps improve lung cancer treatment and enhance the efficacy of immunotherapy.

NLRP3 promotes immune escape by regulating immune checkpoints: A pan-cancer analysis

Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer

NPM3 As a Novel Oncogenic Factor and Poor Prognostic Marker Contributes to Cell Proliferation and Migration in Lung Adenocarcinoma

Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer

Whole transcriptome sequencing indicated the Anti-tumor immunity of NLRP3 in breast cancer

Clinical signature and associated immune metabolism of NLRP1 in pan‐cancer

Lnc-CCNH-8 promotes immune escape by up-regulating PD-L1 in hepatocellular carcinoma

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy

Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma

NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma

Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers

NLRP4 negatively regulates type I interferon response and influences the outcome in anti‐programmed cell death protein (PD)‐1/PD‐ligand 1 therapy

Role of NLRP3 inflammasome activation in HCC cell progression

NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway in colorectal cancer progression and metastatsis

NLRP3 in tumor-associated macrophages predicts a poor prognosis and promotes tumor growth in head and neck squamous cell carcinoma

Upregulated LINC01088 Facilitates Malignant Phenotypes and Immune Escape of Colorectal Cancer by Regulating Micrornas/g3bp1/pd-L1 Axis

Genome-wide analyses reveal the contribution of somatic variants to the immune landscape of multiple cancer types

NLRP3 Deficiency in Hepatocellular Carcinoma Enhances Surveillance of NK-92 through a Modulation of MICA/B

Tumor Mutation Burden-Associated LINC00638/miR-4732-3p/ULBP1 Axis Promotes Immune Escape <i>via</i> PD-L1 in Hepatocellular Carcinoma

A pan-cancer analysis of prognostic significance and immunological role of lysosomal-associated membrane protein 3